[SCHEDULE 13G] Blueprint Medicines Corporation SEC Filing
Pentwater Capital Management LP and Matthew Halbower report beneficial ownership of 3,900,000 shares of Blueprint Medicines Corp common stock, representing 6.0% of the outstanding class based on 64,733,629 shares outstanding. The filing states the shares are directly held by the Pentwater Funds and that voting and dispositive power over these shares is shared (no sole voting or dispositive power reported). The Investment Manager is organized in Delaware and Mr. Halbower is a U.S. citizen; the business office for the reporting persons is 1001 10th Avenue South, Suite 216, Naples, FL. The statement certifies the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing control.
Pentwater Capital Management LP e Matthew Halbower dichiarano la titolarit脿 effettiva di 3.900.000 azioni ordinarie di Blueprint Medicines Corp, pari al 6,0% del capitale sociale in circolazione calcolato su 64.733.629 azioni. La segnalazione indica che le azioni sono detenute direttamente dai Pentwater Funds e che il diritto di voto e il potere dispositivi su tali azioni sono condivisi (non 猫 riportato alcun potere di voto o dispositivo in via esclusiva). L'Investment Manager 猫 costituito in Delaware e il sig. Halbower 猫 cittadino statunitense; l'ufficio commerciale dei soggetti segnalanti 猫 in 1001 10th Avenue South, Suite 216, Naples, FL. La dichiarazione certifica che le partecipazioni sono state acquisite e vengono detenute nell'ordinario svolgimento dell'attivit脿 e non allo scopo di modificare il controllo.
Pentwater Capital Management LP y Matthew Halbower informan ser propietarios beneficiarios de 3.900.000 acciones ordinarias de Blueprint Medicines Corp, lo que representa el 6,0% del capital en circulaci贸n, calculado sobre 64.733.629 acciones en circulaci贸n. La presentaci贸n indica que las acciones est谩n en posesi贸n directa de los Pentwater Funds y que el poder de voto y el poder dispositvo sobre dichas acciones se comparten (no se informa poder de voto o dispositvo exclusivo). El gestor de inversiones est谩 constituido en Delaware y el Sr. Halbower es ciudadano de EE. UU.; la oficina comercial de las personas informantes est谩 en 1001 10th Avenue South, Suite 216, Naples, FL. La declaraci贸n certifica que las participaciones fueron adquiridas y se mantienen en el curso ordinario del negocio y no con el prop贸sito de cambiar el control.
Pentwater Capital Management LP鞕赌 Matthew Halbower電� Blueprint Medicines Corp鞚� 氤错喌欤� 3,900,000欤检棎 雽�頃� 鞁れ鞝� 靻岇湢毳� 氤搓碃頄堨溂氅�, 鞚措姅 齑� 氚滍枆欤检嫕 64,733,629欤� 旮办鞙茧 6.0%鞐� 頃措嫻頃╇媹雼�. 氤搓碃靹滌棎 霐半ゴ氅� 頃措嫻 欤检嫕鞚� Pentwater Funds臧� 歆侅爲 氤挫湢頃橁碃 鞛堨溂氅�, 鞚� 欤检嫕霌れ棎 雽�頃� 鞚橁舶甓� 氚� 觳橂秳甓岇潃 瓿奠湢霅橁碃 鞛堨柎 雼弲 鞚橁舶甓� 霕愲姅 觳橂秳甓岇潃 氤搓碃霅橃 鞎婌晿鞀惦媹雼�. 韴瀽鞖挫毄靷姅 雿鸽澕鞗柎鞐� 靹る霅橃柎 鞛堦碃 Halbower 鞌姅 氙戈淡 鞁滊甓岇瀽鞚措┌; 氤搓碃鞛愳潣 鞓侅梾靻� 欤检唽電� 1001 10th Avenue South, Suite 216, Naples, FL鞛呺媹雼�. 靹彪獏靹滊姅 氤挫湢欤检嫕鞚� 韱奠儊鞝侅澑 鞓侅梾 瓿检爼鞐愳劀 旆摑路氤挫湢霅� 瓴冹澊氅� 歆�氚瓣秾 氤�瓴届潉 氇╈爜鞙茧 頃橃 鞎婌晿鞚岇潉 頇曥澑頃╇媹雼�.
Pentwater Capital Management LP et Matthew Halbower d茅clarent la propri茅t茅 b茅n茅ficiaire de 3 900 000 actions ordinaires de Blueprint Medicines Corp, soit 6,0% du capital en circulation sur la base de 64 733 629 actions. Le dossier indique que les actions sont d茅tenues directement par les Pentwater Funds et que le pouvoir de vote et le pouvoir dispositif sur ces actions sont 辫补谤迟补驳茅蝉 (aucun pouvoir de vote ou dispositif exclusif n'est signal茅). Le gestionnaire de placements est organis茅 dans le Delaware et M. Halbower est citoyen am茅ricain ; le bureau commercial des personnes d茅clarante est situ茅 au 1001 10th Avenue South, Suite 216, Naples, FL. La d茅claration atteste que les participations ont 茅t茅 acquises et sont d茅tenues dans le cours normal des affaires et non dans le but de changer le contr么le.
Pentwater Capital Management LP und Matthew Halbower melden wirtschaftliches Eigentum an 3.900.000 Stammaktien der Blueprint Medicines Corp, was 6,0% des ausstehenden Bestands auf Basis von 64.733.629 Aktien entspricht. Die Meldung gibt an, dass die Aktien direkt von den Pentwater Funds gehalten werden und dass Stimm- und Verf眉gungsgewalt 眉ber diese Aktien geteilt werden (keine alleinige Stimm- oder Verf眉gungsgewalt angegeben). Der Investmentmanager ist in Delaware organisiert und Herr Halbower ist US-Staatsb眉rger; das Gesch盲ftsb眉ro der meldenden Personen befindet sich in 1001 10th Avenue South, Suite 216, Naples, FL. Die Erkl盲rung best盲tigt, dass die Beteiligungen im gew枚hnlichen Verlauf des Gesch盲fts erworben und gehalten werden und nicht mit dem Ziel, die Kontrolle zu 盲ndern.
- Clear disclosure of a >5% stake (3,900,000 shares, 6.0%), meeting SEC reporting requirements
- Shared voting and dispositive power indicates holdings are managed at the fund level rather than concentrated in a single individual's sole authority
- Certification that holdings are in the ordinary course of business and not held to change control
- Concentrated ownership (6.0%) could influence shareholder dynamics and trading liquidity
- Limited detail on the identity and number of the specific Pentwater Funds holding the shares, reducing transparency about the ultimate investors' objectives
Insights
TL;DR: A 6% stake by an activist-capable investment manager is material and could influence shareholder dynamics even if disclosed as non-control.
Pentwater's 6.0% position in Blueprint Medicines is above the 5% reporting threshold and material to investors because it signals concentrated ownership that may affect trading liquidity and governance discussions. The filing reports shared voting and dispositive power rather than sole control, and the shares are held by managed funds rather than the manager personally. The statement's certification that the position is held in the ordinary course reduces, but does not eliminate, the potential for engagement with management or proxy activity. Investors should note the exact share count of 3,900,000 and the outstanding share base used for the calculation (64,733,629).
TL;DR: Ownership structure shows fund-level holdings with shared authority; this is an important disclosure for governance monitoring.
The report clarifies that voting and disposition are exercised jointly, which is typical for fund holdings managed by an adviser. Classification codes (IA, PN for the manager; HC, IN for Mr. Halbower) indicate an investment adviser and related individual reporting. The explicit certification that the stake is not intended to change control is standard but not definitive; the presence of a >5% holder warrants attention from the company's board and governance committees regarding outreach, potential proposals, or strategic dialogue.
Pentwater Capital Management LP e Matthew Halbower dichiarano la titolarit脿 effettiva di 3.900.000 azioni ordinarie di Blueprint Medicines Corp, pari al 6,0% del capitale sociale in circolazione calcolato su 64.733.629 azioni. La segnalazione indica che le azioni sono detenute direttamente dai Pentwater Funds e che il diritto di voto e il potere dispositivi su tali azioni sono condivisi (non 猫 riportato alcun potere di voto o dispositivo in via esclusiva). L'Investment Manager 猫 costituito in Delaware e il sig. Halbower 猫 cittadino statunitense; l'ufficio commerciale dei soggetti segnalanti 猫 in 1001 10th Avenue South, Suite 216, Naples, FL. La dichiarazione certifica che le partecipazioni sono state acquisite e vengono detenute nell'ordinario svolgimento dell'attivit脿 e non allo scopo di modificare il controllo.
Pentwater Capital Management LP y Matthew Halbower informan ser propietarios beneficiarios de 3.900.000 acciones ordinarias de Blueprint Medicines Corp, lo que representa el 6,0% del capital en circulaci贸n, calculado sobre 64.733.629 acciones en circulaci贸n. La presentaci贸n indica que las acciones est谩n en posesi贸n directa de los Pentwater Funds y que el poder de voto y el poder dispositvo sobre dichas acciones se comparten (no se informa poder de voto o dispositvo exclusivo). El gestor de inversiones est谩 constituido en Delaware y el Sr. Halbower es ciudadano de EE. UU.; la oficina comercial de las personas informantes est谩 en 1001 10th Avenue South, Suite 216, Naples, FL. La declaraci贸n certifica que las participaciones fueron adquiridas y se mantienen en el curso ordinario del negocio y no con el prop贸sito de cambiar el control.
Pentwater Capital Management LP鞕赌 Matthew Halbower電� Blueprint Medicines Corp鞚� 氤错喌欤� 3,900,000欤检棎 雽�頃� 鞁れ鞝� 靻岇湢毳� 氤搓碃頄堨溂氅�, 鞚措姅 齑� 氚滍枆欤检嫕 64,733,629欤� 旮办鞙茧 6.0%鞐� 頃措嫻頃╇媹雼�. 氤搓碃靹滌棎 霐半ゴ氅� 頃措嫻 欤检嫕鞚� Pentwater Funds臧� 歆侅爲 氤挫湢頃橁碃 鞛堨溂氅�, 鞚� 欤检嫕霌れ棎 雽�頃� 鞚橁舶甓� 氚� 觳橂秳甓岇潃 瓿奠湢霅橁碃 鞛堨柎 雼弲 鞚橁舶甓� 霕愲姅 觳橂秳甓岇潃 氤搓碃霅橃 鞎婌晿鞀惦媹雼�. 韴瀽鞖挫毄靷姅 雿鸽澕鞗柎鞐� 靹る霅橃柎 鞛堦碃 Halbower 鞌姅 氙戈淡 鞁滊甓岇瀽鞚措┌; 氤搓碃鞛愳潣 鞓侅梾靻� 欤检唽電� 1001 10th Avenue South, Suite 216, Naples, FL鞛呺媹雼�. 靹彪獏靹滊姅 氤挫湢欤检嫕鞚� 韱奠儊鞝侅澑 鞓侅梾 瓿检爼鞐愳劀 旆摑路氤挫湢霅� 瓴冹澊氅� 歆�氚瓣秾 氤�瓴届潉 氇╈爜鞙茧 頃橃 鞎婌晿鞚岇潉 頇曥澑頃╇媹雼�.
Pentwater Capital Management LP et Matthew Halbower d茅clarent la propri茅t茅 b茅n茅ficiaire de 3 900 000 actions ordinaires de Blueprint Medicines Corp, soit 6,0% du capital en circulation sur la base de 64 733 629 actions. Le dossier indique que les actions sont d茅tenues directement par les Pentwater Funds et que le pouvoir de vote et le pouvoir dispositif sur ces actions sont 辫补谤迟补驳茅蝉 (aucun pouvoir de vote ou dispositif exclusif n'est signal茅). Le gestionnaire de placements est organis茅 dans le Delaware et M. Halbower est citoyen am茅ricain ; le bureau commercial des personnes d茅clarante est situ茅 au 1001 10th Avenue South, Suite 216, Naples, FL. La d茅claration atteste que les participations ont 茅t茅 acquises et sont d茅tenues dans le cours normal des affaires et non dans le but de changer le contr么le.
Pentwater Capital Management LP und Matthew Halbower melden wirtschaftliches Eigentum an 3.900.000 Stammaktien der Blueprint Medicines Corp, was 6,0% des ausstehenden Bestands auf Basis von 64.733.629 Aktien entspricht. Die Meldung gibt an, dass die Aktien direkt von den Pentwater Funds gehalten werden und dass Stimm- und Verf眉gungsgewalt 眉ber diese Aktien geteilt werden (keine alleinige Stimm- oder Verf眉gungsgewalt angegeben). Der Investmentmanager ist in Delaware organisiert und Herr Halbower ist US-Staatsb眉rger; das Gesch盲ftsb眉ro der meldenden Personen befindet sich in 1001 10th Avenue South, Suite 216, Naples, FL. Die Erkl盲rung best盲tigt, dass die Beteiligungen im gew枚hnlichen Verlauf des Gesch盲fts erworben und gehalten werden und nicht mit dem Ziel, die Kontrolle zu 盲ndern.
FAQ
How many Blueprint Medicines (BPMC) shares does Pentwater report owning?
Does Pentwater have sole voting control over the BPMC shares?
On what share count is the 6.0% ownership based?
Who are the reporting persons on the Schedule 13G for BPMC?
Is the Pentwater position reported as intended to change control of Blueprint Medicines?
